As pointed out above, the loss of LAMP‐1 immunostaining in FTLD as a whole, compared to AD and controls, appeared to be driven in part by loss of LAMP‐1 from patients with SD and FTLD‐type C pathology. This evidence concerns the gene LAMP1 and Alzheimer disease.